Symbols / CSBR Stock $6.50 +1.25% Champions Oncology, Inc.

Healthcare • Biotechnology • United States • NCM
CSBR (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Robert Brainin
Exch · Country NCM · United States
Market Cap 90.26M
Enterprise Value 88.23M
Income -2.34M
Sales 57.95M
FCF (ttm) 4.70M
Book/sh 0.31
Cash/sh 0.51
Employees 213
Insider 10d —
IPO Feb 02, 2007
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 34.71
Forward P/E 65.00
PEG —
P/S 1.56
P/B 21.10
P/C —
EV/EBITDA -114.29
EV/Sales 1.52
Quick Ratio 0.93
Current Ratio 0.98
Debt/Eq 114.19
LT Debt/Eq —
EPS (ttm) -0.18
EPS next Y 0.10
EPS Growth —
Revenue Growth -2.80%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-07-23
Earnings (prior) 2025-12-15
ROA -4.70%
ROE -47.59%
ROIC —
Gross Margin 45.88%
Oper. Margin -1.13%
Profit Margin -4.04%
Shs Outstand 13.89M
Shs Float 5.19M
Insider Own 26.67%
Instit Own 47.75%
Short Float 1.19%
Short Ratio 7.46
Short Interest 80.60K
52W High 9.63
vs 52W High -32.50%
52W Low 5.50
vs 52W Low 18.18%
Beta 0.40
Impl. Vol. 5.74%
Rel Volume 0.47
Avg Volume 9.13K
Volume 4.29K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $6.42
Price $6.50
Change 1.25%
About

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$6.50
Latest analyst target
3. DCF / Fair value
$6.10
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.50
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-03-12 main Craig-Hallum Buy → Buy $12
2024-12-12 main Craig-Hallum Buy → Buy $8
2024-09-12 up Craig-Hallum Hold → Buy $6
2024-03-13 down Craig-Hallum Buy → Hold —
2023-09-22 main Roth MKM Buy → Buy $8
2021-03-15 main Roth Capital — → Buy $16
2019-11-18 init Benchmark — → Speculative Buy $11
2019-09-20 init Roth Capital — → Buy $9
2019-07-24 down Janney Montgomery Scott Buy → Neutral —
2018-07-17 init Craig-Hallum — → Buy $12
2018-05-15 init Dawson James — → Buy $10
News
RSS: Latest CSBR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-10-30 ACKERMAN JOEL Director — 94,405 $2.10 $198,250
2024-10-31 ACKERMAN JOEL Director — 105,137 $2.10 $276,289
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Total Revenue
56.94
+13.54%
50.16
-6.90%
53.87
+9.69%
49.11
Operating Revenue
56.94
+13.54%
50.16
-6.90%
53.87
+14.91%
46.88
Cost Of Revenue
28.39
-3.44%
29.40
-0.44%
29.53
+24.97%
23.63
Reconciled Cost Of Revenue
28.39
-3.44%
29.40
-0.44%
29.53
+24.97%
23.63
Gross Profit
28.55
+37.59%
20.75
-14.73%
24.34
-4.47%
25.48
Operating Expense
23.71
-14.33%
27.68
-3.86%
28.79
+15.75%
24.87
Research And Development
6.83
-28.49%
9.54
-17.33%
11.54
+23.16%
9.37
Selling General And Administration
16.88
-6.88%
18.13
+5.16%
17.24
+11.27%
15.50
Selling And Marketing Expense
7.54
+6.81%
7.06
+0.89%
7.00
+9.77%
6.38
General And Administrative Expense
9.34
-15.61%
11.07
+8.08%
10.24
+12.32%
9.12
Other Gand A
9.34
-15.61%
11.07
+8.08%
10.24
+12.32%
9.12
Total Expenses
52.10
-8.72%
57.08
-2.13%
58.32
+20.24%
48.50
Operating Income
4.85
+170.02%
-6.92
-55.56%
-4.45
-832.95%
0.61
Total Operating Income As Reported
4.55
+161.90%
-7.36
-39.95%
-5.26
-965.90%
0.61
EBITDA
6.49
+228.33%
-5.05
-129.41%
-2.20
-198.61%
2.23
Normalized EBITDA
6.78
+246.76%
-4.62
-230.87%
-1.40
-162.49%
2.23
Reconciled Depreciation
1.64
-12.16%
1.87
-16.87%
2.25
+38.05%
1.63
EBIT
4.85
+170.02%
-6.92
-55.56%
-4.45
-832.95%
0.61
Total Unusual Items
-0.29
+32.64%
-0.43
+46.10%
-0.81
0.00
Total Unusual Items Excluding Goodwill
-0.29
+32.64%
-0.43
+46.10%
-0.81
0.00
Special Income Charges
-0.29
+32.64%
-0.43
+46.10%
-0.81
0.00
Write Off
—
0.00
-100.00%
0.81
0.00
Net Income
4.70
+164.61%
-7.28
-36.38%
-5.33
-1073.54%
0.55
Pretax Income
4.63
+163.30%
-7.31
-38.75%
-5.27
-1003.43%
0.58
Other Income Expense
-0.22
+43.15%
-0.39
+52.69%
-0.82
-3308.33%
-0.02
Other Non Operating Income Expenses
0.07
+52.08%
0.05
+536.36%
-0.01
+54.17%
-0.02
Tax Provision
-0.07
-134.38%
-0.03
-147.06%
0.07
+94.29%
0.04
Tax Rate For Calcs
0.00
+4100.00%
0.00
-97.62%
0.00
+250.00%
0.00
Tax Effect Of Unusual Items
-0.06
-2728.97%
-0.00
+98.72%
-0.17
0.00
Net Income Including Noncontrolling Interests
4.70
+164.61%
-7.28
-36.38%
-5.33
-1073.54%
0.55
Net Income From Continuing Operation Net Minority Interest
4.70
+164.61%
-7.28
-36.38%
-5.33
-1073.54%
0.55
Net Income From Continuing And Discontinued Operation
4.70
+164.61%
-7.28
-36.38%
-5.33
-1073.54%
0.55
Net Income Continuous Operations
4.70
+164.61%
-7.28
-36.38%
-5.33
-1073.54%
0.55
Normalized Income
4.93
+172.08%
-6.84
-45.68%
-4.70
-957.20%
0.55
Net Income Common Stockholders
4.70
+164.61%
-7.28
-36.38%
-5.33
-1073.54%
0.55
Diluted EPS
0.33
+161.11%
-0.54
-38.46%
-0.39
-1075.00%
0.04
Basic EPS
0.34
+162.96%
-0.54
-38.46%
-0.39
-1075.00%
0.04
Basic Average Shares
13.66
+0.83%
13.55
+0.04%
13.54
+2.61%
13.20
Diluted Average Shares
14.27
+5.31%
13.55
+0.04%
13.54
-4.37%
14.16
Diluted NI Availto Com Stockholders
4.70
+164.61%
-7.28
-36.38%
-5.33
-1073.54%
0.55
Gain On Sale Of PPE
-0.29
+32.64%
-0.43
0.00
—
Line Item Trend 2024-04-30 2023-04-30
Total Assets
26.13
-23.84%
34.31
Current Assets
13.64
-29.90%
19.46
Cash Cash Equivalents And Short Term Investments
2.62
-74.13%
10.12
Cash And Cash Equivalents
2.62
-74.13%
10.12
Cash Financial
2.62
-74.13%
10.12
Receivables
9.53
+18.91%
8.01
Accounts Receivable
4.89
+27.14%
3.84
Receivables Adjustments Allowances
-1.30
-57.70%
-0.82
Other Receivables
5.94
+18.99%
4.99
Prepaid Assets
—
—
Other Current Assets
1.50
+12.58%
1.33
Total Non Current Assets
12.49
-15.89%
14.85
Net PPE
11.97
-17.45%
14.50
Gross PPE
22.36
-3.33%
23.13
Accumulated Depreciation
-10.39
-20.41%
-8.63
Properties
0.00
0.00
Machinery Furniture Equipment
2.40
+2.13%
2.35
Construction In Progress
1.89
-36.27%
2.97
Other Properties
17.76
+0.28%
17.71
Leases
0.32
+185.59%
0.11
Goodwill And Other Intangible Assets
0.34
+0.00%
0.34
Goodwill
0.34
+0.00%
0.34
Other Non Current Assets
0.18
+1133.33%
0.01
Total Liabilities Net Minority Interest
28.04
-5.53%
29.68
Current Liabilities
21.54
-0.88%
21.73
Payables And Accrued Expenses
7.96
+4.68%
7.60
Payables
5.80
+8.74%
5.33
Accounts Payable
5.80
+8.74%
5.33
Current Accrued Expenses
2.16
-4.85%
2.27
Current Debt And Capital Lease Obligation
1.34
+10.68%
1.21
Current Capital Lease Obligation
1.34
+10.68%
1.21
Current Deferred Liabilities
12.09
-5.34%
12.78
Current Deferred Revenue
12.09
-5.34%
12.78
Other Current Liabilities
0.15
+3.45%
0.14
Total Non Current Liabilities Net Minority Interest
6.49
-18.23%
7.94
Long Term Debt And Capital Lease Obligation
6.09
-17.56%
7.39
Long Term Capital Lease Obligation
6.09
-17.56%
7.39
Other Non Current Liabilities
0.40
-27.22%
0.55
Stockholders Equity
-1.90
-141.05%
4.64
Common Stock Equity
-1.90
-141.05%
4.64
Capital Stock
0.01
+0.00%
0.01
Common Stock
0.01
+0.00%
0.01
Share Issued
13.71
+1.15%
13.56
Ordinary Shares Number
13.59
+0.37%
13.54
Treasury Shares Number
0.12
+734.37%
0.01
Additional Paid In Capital
83.38
+1.67%
82.01
Retained Earnings
-84.59
-9.41%
-77.32
Treasury Stock
0.71
+856.76%
0.07
Total Equity Gross Minority Interest
-1.90
-141.05%
4.64
Total Capitalization
-1.90
-141.05%
4.64
Working Capital
-7.90
-247.19%
-2.28
Invested Capital
-1.90
-141.05%
4.64
Total Debt
7.43
-13.59%
8.60
Capital Lease Obligations
7.43
-13.59%
8.60
Net Tangible Assets
-2.24
-152.03%
4.30
Tangible Book Value
-2.24
-152.03%
4.30
Line Item Trend 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Operating Cash Flow
7.39
+220.35%
-6.14
-254.51%
3.97
-38.86%
6.50
Cash Flow From Continuing Operating Activities
7.39
+220.35%
-6.14
-254.51%
3.97
-38.86%
6.50
Net Income From Continuing Operations
4.70
+164.61%
-7.28
-36.38%
-5.33
-1073.54%
0.55
Depreciation Amortization Depletion
1.64
-12.16%
1.87
-16.87%
2.25
+38.05%
1.63
Depreciation And Amortization
1.64
-12.16%
1.87
-16.87%
2.25
+38.05%
1.63
Other Non Cash Items
1.17
+9.94%
1.07
+11.97%
0.95
+21.12%
0.79
Stock Based Compensation
0.65
-41.50%
1.12
+29.40%
0.86
-5.26%
0.91
Provisionand Write Offof Assets
-0.27
-157.14%
0.48
+144.10%
0.20
-33.22%
0.29
Asset Impairment Charge
—
0.00
-100.00%
0.81
0.00
Deferred Tax
-0.18
0.00
—
—
Deferred Income Tax
-0.18
0.00
—
—
Operating Gains Losses
0.29
-32.64%
0.43
—
-0.00
Gain Loss On Sale Of PPE
0.29
-32.64%
0.43
0.00
+100.00%
-0.00
Change In Working Capital
-0.62
+83.76%
-3.82
-190.10%
4.24
+81.64%
2.34
Change In Receivables
-1.44
+27.88%
-1.99
-252.22%
1.31
+146.42%
-2.82
Changes In Account Receivables
-1.44
+27.88%
-1.99
-252.22%
1.31
+146.42%
-2.82
Change In Prepaid Assets
0.14
+186.23%
-0.17
+9.24%
-0.18
+1.60%
-0.19
Change In Payables And Accrued Expense
-1.35
-480.34%
0.36
-84.66%
2.32
+100.52%
1.16
Change In Accrued Expense
0.40
+462.39%
-0.11
+24.83%
-0.14
-179.23%
0.18
Change In Payable
-1.75
-476.13%
0.47
-81.14%
2.46
+153.08%
0.97
Change In Account Payable
-1.75
-476.13%
0.47
-81.14%
2.46
+153.08%
0.97
Change In Other Working Capital
3.35
+590.34%
-0.68
-140.04%
1.71
-64.57%
4.82
Change In Other Current Assets
0.00
+100.00%
-0.17
0.00
—
Change In Other Current Liabilities
-1.32
-13.26%
-1.17
-28.89%
-0.91
-43.74%
-0.63
Investing Cash Flow
-0.39
+53.47%
-0.84
+70.89%
-2.87
-20.47%
-2.38
Cash Flow From Continuing Investing Activities
-0.39
+53.47%
-0.84
+70.89%
-2.87
-20.47%
-2.38
Net PPE Purchase And Sale
-0.39
+53.47%
-0.84
+70.89%
-2.87
-20.47%
-2.38
Purchase Of PPE
-0.39
+53.47%
-0.84
+70.89%
-2.87
-20.47%
-2.38
Capital Expenditure
-0.39
+53.47%
-0.84
+70.89%
-2.87
-20.47%
-2.38
Financing Cash Flow
0.17
+132.26%
-0.53
-4890.91%
0.01
-94.69%
0.21
Cash Flow From Continuing Financing Activities
0.17
+132.26%
-0.53
-4890.91%
0.01
-94.69%
0.21
Net Issuance Payments Of Debt
-0.15
-2.74%
-0.15
0.00
0.00
Repayment Of Debt
-0.15
-2.74%
-0.15
0.00
0.00
Long Term Debt Payments
-0.15
-2.74%
-0.15
0.00
0.00
Net Long Term Debt Issuance
-0.15
-2.74%
-0.15
0.00
0.00
Net Common Stock Issuance
0.00
+100.00%
-0.63
-756.76%
-0.07
0.00
Common Stock Payments
0.00
+100.00%
-0.63
-756.76%
-0.07
0.00
Repurchase Of Capital Stock
0.00
+100.00%
-0.63
-756.76%
-0.07
0.00
Proceeds From Stock Option Exercised
0.32
+26.48%
0.25
+197.65%
0.09
-58.94%
0.21
Changes In Cash
7.17
+195.56%
-7.50
-775.07%
1.11
-74.28%
4.32
Beginning Cash Position
2.62
-74.13%
10.12
+12.33%
9.01
+92.17%
4.69
End Cash Position
9.79
+273.76%
2.62
-74.13%
10.12
+12.33%
9.01
Free Cash Flow
7.00
+200.34%
-6.97
-733.91%
1.10
-73.26%
4.11
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category